Systemic delivery of chTNT-3/CpG immunoconjugates for immunotherapy in murine solid tumor models

Area of Science:

• Immunology
• Oncology
• Biotechnology

Background:

• CpG oligodeoxynucleotides (CpG) activate the immune system by mimicking microbial DNA.
• Systemic delivery of CpG is limited by rapid clearance and lack of tumor accumulation.
• Targeting tumor necrotic centers with antibodies can enhance localized drug delivery.

Purpose of the Study:

• To evaluate the efficacy of CpG conjugated to chTNT-3 (chTNT-3/CpG) for cancer immunotherapy.
• To compare the anti-tumor activity of chTNT-3/CpG with free CpG and control constructs.
• To determine if chTNT-3/CpG can improve immune system activation within tumors.

Main Methods:

• Chemical conjugation of CpG to the chTNT-3 antibody.
• In vitro assessment of immune stimulation.
• In vivo studies using Colon 26 adenocarcinoma and B16-F10 melanoma mouse models.
• Systemic administration of chTNT-3/CpG, free CpG, and control constructs.

Main Results:

• chTNT-3/CpG administration significantly delayed tumor growth and improved survival in both cancer models.
• Tumor volumes were reduced by up to 72% in Colon 26 and 79% in B16 models compared to saline controls.
• Systemically delivered free CpG or CpG conjugated to an isotype control antibody showed no significant anti-tumor effects.
• chTNT-3/CpG demonstrated retained immunostimulatory activity and effective tumor accumulation.

Conclusions:

• chTNT-3/CpG conjugate is a promising strategy for systemic cancer immunotherapy.
• This approach overcomes the limitations of free CpG, enabling targeted delivery and enhanced anti-tumor immune responses.
• chTNT-3/CpG offers a potential solution for improving cancer treatment efficacy in preclinical and clinical settings.